Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary) ; Adalimumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms VOYAGE 2
- Sponsors Janssen Research & Development
- 26 Sep 2023 Results of post-hoc analysis evaluating the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years, published in the Dermatology and Therapy
- 15 Sep 2023 Results from VOYAGE-1 and -2 studies , evaluating guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis, published in the Dermatology and Therapy
- 01 Sep 2023 Results of post hoc analysis (n=199 in the Asian subpopulation from studies VOYAGE 1 and VOYAGE 2) assessing Efficacy of guselkumab in difficult-to-treat psoriasis regions published in the Journal of Dermatology.